IL10 and renal fibrosis: On the other hand, for PEGDA 2000 and 4,000 NLGs, the slowed release of 40% may be applied to renal fibrosis treatment by delivering mRNA or cytokines like IL-10 (Nastase et al., 2018), or ocular applications such as delivery to the back of the eye for treating ischemic retinopathies and macular edema (Ozaki et al., 1997; Kompella et al., 2010), where a much slower release over a longer period of time is desired.